Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs PAGSEG Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.98 (market cap $1.74B), while PAGSEG Inc trades at $10.65 (market cap $2.94B). The key difference: PAGSEG Inc is the larger of the two by market cap, and PAGSEG Inc pays a 10.49% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and PAGSEG Inc for 26 Days on average.
| NUVB | PAGS | |
|---|---|---|
Market Cap | $1.74B | $2.94B |
Volume | 9,289,619 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $9.54 | $12.00 |
52-Week Low | $3.41 | $8.44 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $1.33B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PAGS trades at $10.51, down 1.96% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong profitability with a 10.45% net income margin and trades at a discounted valuation with a P/E of 7.1 and P/S of 0.74. Recent earnings beat expectations in Q2 2026, and a $0.28 dividend is scheduled for September 2026.
The outlook is positive given undervaluation, profitability, and dividend yield, but risks include a recent earnings miss in Q1 2026 and a projected negative net cash flow for 2026. Investor sentiment is supported by strong analyst buy ratings, though technical indicators show some overbought conditions with RSI at 78.08.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
